Drug Trial Radar · NCT02802423
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Apr 30, 2028
Study completion Aug 28, 2028
Sponsor
- Lead sponsor
- BioLite, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 20 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.
Conditions
- Triple Negative Breast Cancer
Interventions
BLEX 404 Oral LiquidDrug
BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Dose-limiting toxicity (DLT) observationTime frame: 3 weeks (1 cycle)
- Phase II: Overall response rate (PR + CR)Time frame: 12 weeks (4 cycles)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.